The CorEvitas Psoriasis (PSO) Registry

Enrolling by invitation

Conditions studied: Psoriasis

In brief

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Key facts

Study ID

NCT02707341

Run by

CorEvitas

People needed

10000

Starts

2015-04-01

Expected to finish

2100-12-01

Last updated by the study team

2026-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient must:
• Have been diagnosed with psoriasis by a dermatologist.
• Be at least 18 years of age or older.
• Be willing and able to provide written consent for participation in the registry.
• Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth.
• Meet one of the following criteria.
• Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲:

You may not qualify if…

• Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.